This article is a correction to:
Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
Jenna M. Faircloth1*
Neelam D. Bhatt1*Corey A. Chartan2Ryan D. Coleman2Natalie Villafranco3Fadel E. Ruiz3Raysa Morales-Demori4Elise Whalen5Erin Ely5Rozmeen Fombin5
Nidhy P. Varghese3
- 1Department of Pharmacy, Texas Children’s Hospital, Houston, TX, United States
- 2Department of Pediatrics, Division of Critical Care and Pulmonology, Baylor College of Medicine, Texas Children’s Hospital, Houston, TX, United States
- 3Department of Pediatrics, Division of Pulmonology, Baylor College of Medicine, Texas Children’s Hospital, Houston, TX, United States
- 4Department of Pediatrics, Division of Critical Care, Baylor College of Medicine, Texas Children’s Hospital, Houston, TX, United States
- 5Department of Pulmonary Medicine, Texas Children’s Hospital, Houston, TX, United States
A Corrigendum on
Case Report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
By Faircloth JM, Bhatt ND, Chartan CA, Coleman RD, Villafranco N, Ruiz FE, Morales-Demori R, Whalen E, Ely E, Fombin R, Varghese NP. (2023) Front Pediatr. 11:1050508. doi: 10.3389/fped.2023.1050508
In the published article, there was an error. The text of the article is corrected to reflect the most current pediatric selexipag data available at time of publication. This original statement in the abstract was from when the center-specific selexipag process was developed and implemented (April 2020). However by the time of publication (2023), more robust data on selexipag use was available and the manuscript is now corrected to reflect this.
A correction has been made to the Abstract section. The sentence previously stated:
“Although experience in the pediatric population is limited to case reports in older adolescent patients and selexipag is not approved for use in the pediatric pulmonary hypertension population, many pediatric centers are expanding the use of this therapy to this population.”
The corrected sentence appears below:
“Although experience in the pediatric population is generally limited and selexipag is not approved for use in the pediatric pulmonary hypertension population, many pediatric centers are expanding the use of this therapy to the younger population.”
A correction has been made to the Introduction section, paragraph two. The sentence previously stated:
“Therefore, although experience in the pediatric population is limited primarily to case reports in adolescent patients and selexipag is not approved for use in the pediatric pulmonary hypertension population, many pediatric centers are expanding the use of this therapy to this population (4–8).”
The corrected sentence appears below:
“Despite the lack of randomized clinical trials in pediatrics, an increasing number of centers are reporting the successful use of selexipag through case reports, series and observational studies (4–8).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: pediatric pulmonary hypertension, selexipag, treprostinil, initiation, transition, prostacyclin
Citation: Faircloth JM, Bhatt ND, Chartan CA, Coleman RD, Villafranco N, Ruiz FE, Morales-Demori R, Whalen E, Ely E, Fombin R and Varghese NP (2023) Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration. Front. Pediatr. 11:1275389. doi: 10.3389/fped.2023.1275389
Received: 9 August 2023; Accepted: 10 August 2023;
Published: 21 August 2023.
Approved by: Frontiers in Pediatrics, Frontiers Media SA, Switzerland
© 2023 Faircloth, Bhatt, Chartan, Coleman, Villafranco, Ruiz, Morales-Demori, Whalen, Ely, Fombin and Varghese. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jenna M. Faircloth am1mYWlyY2xAdGV4YXNjaGlsZHJlbnMub3Jn Neelam D. Bhatt bmRiaGF0dDJAdGV4YXNjaGlsZHJlbnMub3Jn